NCT00647348.

Trial name or title	Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis (MS‐STAT)
Methods	A Phase II Randomised, Placebo‐Controlled Clinical Trial
Participants	140 Patients with Secondary‐Progressive MS EDSS 4.0 ‐ 6.5 inclusive Women of childbearing age will be required to use appropriate methods of contraception Written informed consent 18 ‐ 65 years
Interventions	Intervention group: simvastatin 80 mg Control group: placebo
Outcomes	Primary outcomes: quantitative MRI analysis to measure cerebral atrophy, and inflammation. Secondary Outcomes: evaluations of disability (EDSS, MSFC, MSIS‐29), quality of life (SF‐36), cognitive and behavioural function tests.
Starting date	January 2008
Contact information	David Wilkie, BA, MA, Tel:0044 (0) 208 383 0675 Email: d.wilkie@imperial.ac.uk
Notes	Sponsored by Imperial College London http://clinicaltrials.gov/ct2/show/NCT00647348

EDSS: Expanded Disability Status Scale